This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Ninlaro (ixazomib)
General Description:
Ninlaro (ixazomib) is an oral proteasome inhibitor used for the treatment of multiple myeloma. It works by blocking the proteasome, a cellular complex responsible for breaking down proteins, thereby causing the accumulation of abnormal proteins in cancer cells, leading to their death.
Ninlaro provides a convenient oral treatment option for patients with multiple myeloma, often used in combination with other therapies to improve efficacy.
Disease Indications:
Multiple Myeloma
Manufacturer:
Takeda Pharma A/S
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan)
• Therapeutic Goods Administration (TGA, Australia)
Package:
• Capsules × 3 capsules of 2.3 mg
• Capsules × 3 capsules of 3 mg
• Capsules × 3 capsules of 4 mg
Shipping:
Room Temperature Shipping
Ninlaro can be shipped using standard delivery, maintaining a consistent room temperature of 15–25°C during transit. This ensures the medicine’s stability and effectiveness without the need for specialized cold chain handling.
How to Access Ninlaro (ixazomib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Ninlaro (ixazomib) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
